Home
LXRX
LXRX News

Latest Lexicon Pharmaceuticals Inc. (LXRX) News on November 10, 2025

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates

Zacks

4 days ago

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Beats Revenue Estimates

Associated Press Finance

4 days ago

Lexicon: Q3 Earnings Snapshot

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

GlobeNewswire

4 days ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

Zacks

5 days ago

Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

GlobeNewswire

6 days ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

How Viatris Prevents and Manages NCDs

ACCESS Newswire

a month ago

How Viatris Prevents and Manages NCDs

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

GlobeNewswire

a month ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

GlobeNewswire

a month ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

MT Newswires

2 months ago

Lexicon Pharmaceuticals Says FDA Delays Feedback on Zynquista Data

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

MT Newswires

2 months ago

Lexicon Pharmaceuticals Submits Additional Data to US FDA for Zynquista

GlobeNewswire

2 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

GlobeNewswire

5 months ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

GlobeNewswire

5 months ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

Zacks

5 months ago

MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study

Ulta Stock Jumps as Beauty Product Spending Continues

Investopedia

5 months ago

Ulta Stock Jumps as Beauty Product Spending Continues

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

GlobeNewswire

5 months ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

GlobeNewswire

5 months ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt

Benzinga

5 months ago

Northrop Grumman Raises $1 Billion Via Debt

The York Water Company Files a Rate Request Based on $145 Million in Investment

GlobeNewswire

5 months ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

GlobeNewswire

5 months ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

Newsfile

5 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

GlobeNewswire

5 months ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

GlobeNewswire

5 months ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential

Insider Monkey

6 months ago

Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside Potential

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

GlobeNewswire

6 months ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Simply Wall St.

6 months ago

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna

Yahoo Finance

6 months ago

Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Septerna

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

GuruFocus.com

6 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships and ...

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

Zacks

6 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Lags Revenue Estimates

Associated Press Finance

6 months ago

Lexicon: Q1 Earnings Snapshot

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

GlobeNewswire

6 months ago

Lexicon Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Zacks

7 months ago

LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire

7 months ago

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

MT Newswires

7 months ago

Social Buzz: Wallstreetbets Stocks Mixed Premarket Tuesday; Tesla to Advance, Lexicon Pharmaceuticals to Decline

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1

Investor's Business Daily

7 months ago

Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1

MT Newswires

7 months ago

Top Midday Gainers

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

Pharmaceutical Technology

7 months ago

Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug

MT Newswires

7 months ago

Sector Update: Health Care Stocks Steady Premarket Friday

MT Newswires

7 months ago

Lexicon Pharmaceuticals Enters License Agreement With Novo Nordisk for Obesity Drug; Shares Jump

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

GlobeNewswire

7 months ago

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

8 months ago

Lexicon Pharmaceuticals Inc (LXRX) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Zacks

8 months ago

Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates

Associated Press Finance

8 months ago

Lexicon: Q4 Earnings Snapshot

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

MT Newswires

8 months ago

Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

MT Newswires

8 months ago

Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

GlobeNewswire

8 months ago

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

GlobeNewswire

9 months ago

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

GlobeNewswire

10 months ago

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey

10 months ago

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10

MT Newswires

10 months ago

Lexicon Pharmaceuticals Names Scott Coiante Finance Chief

Lexicon Appoints Scott Coiante as Chief Financial Officer

GlobeNewswire

10 months ago

Lexicon Appoints Scott Coiante as Chief Financial Officer

Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%

Simply Wall St.

10 months ago

Private equity firms account for 47% of Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) ownership, while institutions account for 33%

MT Newswires

a year ago

Lexicon Fails to Secure FDA Approval for Zynquista -- Shares Fall After Hours

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

GlobeNewswire

a year ago

Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Lexicon completes subject enrolment for DPNP trial of LX9211

Clinical Trials Arena

a year ago

Lexicon completes subject enrolment for DPNP trial of LX9211

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

GlobeNewswire

a year ago

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon Pharmaceuticals to Participate in December Investor Conferences

GlobeNewswire

a year ago

Lexicon Pharmaceuticals to Participate in December Investor Conferences

MT Newswires

a year ago

Sector Update: Health Care

MT Newswires

a year ago

HC Wainwright Cuts Price Target on Lexicon Pharmaceuticals to $4 From $6, Maintains Buy Rating

MT Newswires

a year ago

Lexicon Pharmaceuticals to Cut 60% of Workforce

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

GlobeNewswire

a year ago

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA

Lexicon to disband sales team, lay off 60% of staff

BioPharma Dive

a year ago

Lexicon to disband sales team, lay off 60% of staff

Lexicon Appoints Ivan H. Cheung to Board of Directors

GlobeNewswire

a year ago

Lexicon Appoints Ivan H. Cheung to Board of Directors

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week

Simply Wall St.

a year ago

Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

GlobeNewswire

a year ago

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

GuruFocus.com

a year ago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ...

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates

Zacks

a year ago

Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates

Associated Press Finance

a year ago

Lexicon: Q3 Earnings Snapshot

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For

GuruFocus.com

a year ago

Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

GlobeNewswire

a year ago

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference

A diabetes drug, twice rejected, stumbles again — but its developer persists

Pharma Voice

a year ago

A diabetes drug, twice rejected, stumbles again — but its developer persists

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire

a year ago

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

GlobeNewswire

a year ago

Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

GlobeNewswire

a year ago

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss

MT Newswires

a year ago

Sector Update: Health Care Stocks Rise Late Afternoon

MT Newswires

a year ago

Top Midday Decliners

MT Newswires

a year ago

Lexicon Pharmaceuticals Says FDA Panel Opposes Zynquista for Type 1 Diabetes and Kidney Disease

MT Newswires

a year ago

Top Premarket Decliners

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire

a year ago

Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting

TipRanks

a year ago

FDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

GlobeNewswire

a year ago

New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN Kidney Week 2024

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

GlobeNewswire

a year ago

Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe

BioPharma Dive

a year ago

Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe

Lexicon partners Viatris for global expansion of sotagliflozin

Pharmaceutical Technology

a year ago

Lexicon partners Viatris for global expansion of sotagliflozin

MT Newswires

a year ago

Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

GlobeNewswire

a year ago

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

PR Newswire

a year ago

Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...

GuruFocus.com

a year ago

Lexicon Pharmaceuticals Inc (LXRX) Q2 2024 Earnings Call Highlights: Strategic Advancements ...

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

GlobeNewswire

a year ago

Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

MT Newswires

a year ago

Lexicon Pharmaceuticals COO Jeff Wade Steps Down

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

GlobeNewswire

a year ago

Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer

Share on Social Networks: